Immungenetics is a leading company in the therapeutic targeting of ABC transporters at the blood brain barrier. A universe of 49 known ABC transporter proteins specifically regulate the exchange of substances from the Central Nervous System to the bloodstream and vice versa, safeguarding our brain. Dysfunctional transport mechanisms like the impaired clearance of toxic substances may lead to neurodegenerative processes.


Immungenetics is taking a first in class, proprietary drug for this novel mechanism of action into the clinic which activates ABC-transporter proteins in charge of the export of toxic ABeta. The company is carrying out Phase II clinical trial for Alzheimer's Diagnosis. The drug also serves as a trigger for the first blood-based predictive assay for (Early Onset) Alzheimer's, Dementia and Parkinson's Disease in development (companion diagnostics).